ScheBo®• Biotech AG is an innovative biotech company that is active in the fields of drug development and the development, production and marketing of diagnostics. ScheBo®• Biotech AG is developing novel cancer therapies for the treatment of various solid tumours and their metastases. ScheBo®• Biotech AG was founded by the biochemists and molecular biologists Ursula Scheefers-Borchel, Ph.D., and Hans Scheefers, Ph.D. in 1989.

Subsidiaries

ScheBo®• Biotech UK Ltd., founded: 1999

ScheBo®• Biotech USA Inc., founded: 2001

The Company

– is completely privately funded and independent,

– operates internationally,

– discovers and develops new drug candidates and diagnostics.

Worldwide Innovations

R&D and manufacturing led to the successful launch and sales of the following products:

– ScheBo®• Pancreatic Elastase 1 Serum Test (launched in 1993)

– ScheBo®• Pancreatic Elastase 1 Stool Test (launched in 1994)

– ScheBo®• Tumor M2-PK™ EDTA Plasma Test* (launched in 1998)

– ScheBo®• Elastase Canine Test (launched in 1999)

– ScheBo®• Brainostic™ Western Blotting Test (launched in 2000)

– ScheBo®• Quick-Prep™ (launched in 2002)

– ScheBo®• Tumor M2-PK™ Stool Test, Laboratory* (launched in 2003)

– ScheBo®• Tumor M2-PK™ Stool Test, Pharmacy* (launched in 2003)

– ScheBo®• Pancreatic Elastase 1 Stool Test (fast) (launched in 2004)

– ScheBo®• Brainostic™ GFAP ELISA (launched in 2004)

– ScheBo®• Pancreatic Elastase 1 Serum Test (fast) (launched in 2005)

– ScheBo®• M2-PK Quick™ (lateral flow test)* (launched in 2007)

* Info: www.darmkrebstest.de; www.metabolic-database.com

Unique Selling Proposition

Innovative diagnostics: 1993 ScheBo®• Biotech AG launched the worldwide first non-invasive, inexpensive routine test procedure for monitoring the exocrine function of the pancreas. Today well-reputed clinicians and medical textbooks regard the ScheBo®• Pancreatic Elastase 1 ELISA, based on two monoclonal antibodies, as the “gold-standard” for non-invasive pancreatic exocrine function testing. ScheBo®• Biotech AG is world market leader for this FDA-cleared product. Continuous innovation and strong customer focus have made ScheBo®• Biotech AG a leading biopharmaceutical company.

Closing a gap: 1998 ScheBo®• Biotech AG launched the ScheBo®• Tumor M2-PK™ EDTA-Plasma Test, the first test worldwide that is able to detect a metabolic state, specific for 11 cancer entities, e.g. esophagus, breast, lung, gastric, pancreas, prostate, kidney, renal, colon/rectum and cancer of the ovary. The predictive value of Tumor M2-PK reflects tumor activity and aggressiveness and gives clinicians additional information that is not provided by state-of-the-art procedures. Thus, the ScheBo®• Tumor M2-PK™ EDTA-Plasma Test closes a gap in clinical practice of cancer treatment management.

Fighting cancer, colorectal cancer screening: 2003 ScheBo®• Biotech AG launched the ScheBo®• Tumor M2-PK™ Stool Test, the first test detecting pyruvate kinase in stool, a new tool for colorectal cancer screening. This patented test is superior to the well-known occult blood stool tests. The new procedure has a sensitivity of 85 % and a specificity of 95 %. 2007 ScheBo®• Biotech AG launched the ScheBo®• M2-PK Quick™, a worldwide new lateral flow test for colorectal cancer screening. Thereby, ScheBo®• Biotech AG hopes to be able to significantly improve colorectal cancer patients’ chances of being cured.

Fighting BSE: 2000/2004 ScheBo®• Biotech AG launched different ScheBo®• Brainostic™ Tests which allow the detection of brain and spinal cord (risk material) in meat products.